Phathom Pharmaceuticals (PHAT) Total Liabilities (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Total Liabilities of $671.3 million for Q2 2026, up 2.33% year-over-year from $656.1 million in Q2 2025, and up 4.56% quarter-over-quarter from $642.1 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Total Liabilities (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Total Liabilities for 9 consecutive years, with $671.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities rose 2.33% year-over-year to $671.3 million; the TTM figure through Jun 2026 stood at $671.3 million (up 2.33% YoY), while the FY2025 annual figure was $697.3 million, up 10.35% from the prior year.
- Total Liabilities grew to $671.3 million in Q2 2026 per PHAT's latest filing, from $642.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $697.3 million in Q4 2025 and bottomed at $111.0 million in Q1 2022.
- Historically, Total Liabilities has averaged $458.3 million across 5 years, with a median of $529.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 167.43% — and 2026, when it advanced 1.5%.
- Phathom Pharmaceuticals' Total Liabilities stood at $239.6 million in 2022, then surged by 103.07% to $486.6 million in 2023, then rose by 29.86% to $631.9 million in 2024, then rose by 10.35% to $697.3 million in 2025, then declined by 3.72% to $671.3 million in 2026.
- Business Quant data shows PHAT's Total Liabilities at $671.3 million in Q2 2026, $642.1 million in Q1 2026, and $697.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 671.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 671.35 Mn |
| Mar 31, 2026 | 642.08 Mn |
| Dec 31, 2025 | 697.32 Mn |
| Sep 30, 2025 | 662.82 Mn |
| Jun 30, 2025 | 656.05 Mn |
| Mar 31, 2025 | 632.58 Mn |
| Dec 31, 2024 | 631.90 Mn |
| Sep 30, 2024 | 574.16 Mn |
| Jun 30, 2024 | 553.21 Mn |
| Mar 31, 2024 | 505.00 Mn |
| Dec 31, 2023 | 486.60 Mn |
| Sep 30, 2023 | 254.77 Mn |
| Jun 30, 2023 | 247.44 Mn |
| Mar 31, 2023 | 234.21 Mn |
| Dec 31, 2022 | 239.62 Mn |
| Sep 30, 2022 | 228.35 Mn |
| Jun 30, 2022 | 220.50 Mn |
| Mar 31, 2022 | 111.01 Mn |
| Dec 31, 2021 | 117.28 Mn |
| Sep 30, 2021 | 124.90 Mn |